Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra di Bacco

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Oncogene|August 23, 2003
The secreted glycoprotein CREG inhibits cell growth dependent on the mannose-6-phosphate/insulin-like growth factor II receptorAlessandra Di Bacco, Grace Gill
Cell Cycle (Georgetown, Tex.)|November 15, 2006
SUMO-specific proteases and the cell cycle. An essential role for SENP5 in cell proliferationAlessandra Di Bacco, Grace Gill
Oncotarget|January 5, 2018
Optimizing therapy for del(17p) multiple myelomaHervé Avet-Loiseau, Paul G Richardson, Alessandra di Bacco
Molecular and Cellular Biology|June 2, 2006
The SUMO-specific protease SENP5 is required for cell divisionAlessandra Di Bacco, Jian Ouyang, Hsiang-Ying Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2005
The crystal structure of CREG, a secreted glycoprotein involved in cellular growth and differentiationMichael Sacher, Alessandra Di Bacco, Vladimir V Lunin, et al.
Cancer Research|April 3, 2008
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survivalKaiko Kunii, Lenora Davis, Julie Gorenstein, et al.
European Journal of Haematology|May 1, 2020
Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activationAjeeta B Dash, Jacob Zhang, Lei Shen, et al.
Blood|June 7, 2014
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myelomaShaji K Kumar, William I Bensinger, Todd M Zimmerman, et al.
Blood|June 13, 2014
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsPaul G Richardson, Rachid Baz, Michael Wang, et al.
Haematologica|June 30, 2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myelomaJesús F San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Oncogene|August 23, 2003
The secreted glycoprotein CREG inhibits cell growth dependent on the mannose-6-phosphate/insulin-like growth factor II receptorAlessandra Di Bacco, Grace Gill
Cell Cycle (Georgetown, Tex.)|November 15, 2006
SUMO-specific proteases and the cell cycle. An essential role for SENP5 in cell proliferationAlessandra Di Bacco, Grace Gill
Oncotarget|January 5, 2018
Optimizing therapy for del(17p) multiple myelomaHervé Avet-Loiseau, Paul G Richardson, Alessandra di Bacco
Molecular and Cellular Biology|June 2, 2006
The SUMO-specific protease SENP5 is required for cell divisionAlessandra Di Bacco, Jian Ouyang, Hsiang-Ying Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2005
The crystal structure of CREG, a secreted glycoprotein involved in cellular growth and differentiationMichael Sacher, Alessandra Di Bacco, Vladimir V Lunin, et al.
Cancer Research|April 3, 2008
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survivalKaiko Kunii, Lenora Davis, Julie Gorenstein, et al.
European Journal of Haematology|May 1, 2020
Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activationAjeeta B Dash, Jacob Zhang, Lei Shen, et al.
Blood|June 7, 2014
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myelomaShaji K Kumar, William I Bensinger, Todd M Zimmerman, et al.
Blood|June 13, 2014
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsPaul G Richardson, Rachid Baz, Michael Wang, et al.
Haematologica|June 30, 2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myelomaJesús F San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, et al.
Pageof 3